Drug-induced Q-T prolongation

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Drug therapy may induce Q-T prolongation by alteration of potassiumion currents in cardiac cells, resulting in abnormal repolarization. Q-T prolongation, whether congenital or acquired, has been associated with the development of the malignant dysrhythmia Torsade de Pointes (TdP), which may result in sudden death. Recent regulatory actions and drug withdrawals due to Q-T prolongation or TdP have focused attention on this issue. Although our understanding of the pathophysiology continues to evolve, both patient and medication factors contribute to the individual risk of drug-induced Q-T prolongation or TdP. The clinician should be aware of these issues when prescribing new drugs and should weigh the risks and benefits carefully when prescribing drugs known to prolong the Q-T interval.

Original languageEnglish
Pages (from-to)1125-1144
Number of pages20
JournalMedical Clinics of North America
Volume89
Issue number6
DOIs
StatePublished - Nov 2005

Fingerprint

Torsades de Pointes
Drug Prescriptions
Pharmaceutical Preparations
Sudden Death
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Drug-induced Q-T prolongation. / Kao, Louise; Furbee, R.

In: Medical Clinics of North America, Vol. 89, No. 6, 11.2005, p. 1125-1144.

Research output: Contribution to journalArticle

@article{bc5ceb6603734a60b87e121185d6893f,
title = "Drug-induced Q-T prolongation",
abstract = "Drug therapy may induce Q-T prolongation by alteration of potassiumion currents in cardiac cells, resulting in abnormal repolarization. Q-T prolongation, whether congenital or acquired, has been associated with the development of the malignant dysrhythmia Torsade de Pointes (TdP), which may result in sudden death. Recent regulatory actions and drug withdrawals due to Q-T prolongation or TdP have focused attention on this issue. Although our understanding of the pathophysiology continues to evolve, both patient and medication factors contribute to the individual risk of drug-induced Q-T prolongation or TdP. The clinician should be aware of these issues when prescribing new drugs and should weigh the risks and benefits carefully when prescribing drugs known to prolong the Q-T interval.",
author = "Louise Kao and R Furbee",
year = "2005",
month = "11",
doi = "10.1016/j.mcna.2005.06.003",
language = "English",
volume = "89",
pages = "1125--1144",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Drug-induced Q-T prolongation

AU - Kao, Louise

AU - Furbee, R

PY - 2005/11

Y1 - 2005/11

N2 - Drug therapy may induce Q-T prolongation by alteration of potassiumion currents in cardiac cells, resulting in abnormal repolarization. Q-T prolongation, whether congenital or acquired, has been associated with the development of the malignant dysrhythmia Torsade de Pointes (TdP), which may result in sudden death. Recent regulatory actions and drug withdrawals due to Q-T prolongation or TdP have focused attention on this issue. Although our understanding of the pathophysiology continues to evolve, both patient and medication factors contribute to the individual risk of drug-induced Q-T prolongation or TdP. The clinician should be aware of these issues when prescribing new drugs and should weigh the risks and benefits carefully when prescribing drugs known to prolong the Q-T interval.

AB - Drug therapy may induce Q-T prolongation by alteration of potassiumion currents in cardiac cells, resulting in abnormal repolarization. Q-T prolongation, whether congenital or acquired, has been associated with the development of the malignant dysrhythmia Torsade de Pointes (TdP), which may result in sudden death. Recent regulatory actions and drug withdrawals due to Q-T prolongation or TdP have focused attention on this issue. Although our understanding of the pathophysiology continues to evolve, both patient and medication factors contribute to the individual risk of drug-induced Q-T prolongation or TdP. The clinician should be aware of these issues when prescribing new drugs and should weigh the risks and benefits carefully when prescribing drugs known to prolong the Q-T interval.

UR - http://www.scopus.com/inward/record.url?scp=26844476445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844476445&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2005.06.003

DO - 10.1016/j.mcna.2005.06.003

M3 - Article

C2 - 16227057

AN - SCOPUS:26844476445

VL - 89

SP - 1125

EP - 1144

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 6

ER -